TUCSON, Ariz.--(BUSINESS WIRE)--ImaRx Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing therapies for vascular disorders associated with blood clots, today announced that Bradford A. Zakes was named President and Chief Executive Officer by the Company’s Board of Directors. Mr. Zakes most recently served as the Company’s Chief Operating Officer.
“Brad has demonstrated leadership capability throughout his career, and the Board felt strongly that he would provide the continuity needed during this stage of the Company’s development and growth,” said ImaRx’s Chairman Richard E. Otto. “On behalf of the entire Board, we look forward to working with and supporting Brad and his management team.”
Mr. Zakes replaces Dr. Evan Unger who resigned as President and CEO in October. Dr. Unger remains a member of the ImaRx Board of Directors and is Chairman of the Company’s Scientific Advisory Board. “I’m pleased that the Board has appointed Brad to lead the Company,” said Unger. “His understanding of ImaRx’s technology and market opportunity are outstanding, and he has the right skills to move the Company forward, thus affording me the opportunity to focus on the scientific development of ImaRx.”
Prior to joining ImaRx, Mr. Zakes served as Director, Business Management at ICOS Corporation, a biotechnology company, from December 2001 to August 2005. From March 1999 to December 2001, Mr. Zakes served as President of Heart Research Centers International, a clinical research organization. Mr. Zakes holds a B.S. in Biology from Oregon State University, an M.S. degree in Toxicology from the American University and an M.B.A. from Duke University’s Fuqua School of Business.
About ImaRx Therapeutics
The “Clotbusting” Company(TM).
ImaRx Therapeutics is developing and commercializing therapies for vascular disorders associated with blood clots based on two platforms: urokinase-based thrombolytics and SonoLysis, a therapy combining the company’s proprietary bubbles with ultrasound to treat stroke and other vascular diseases. ImaRx’s goal is to improve patient outcomes by restoring critical blood flow to vital organs and tissues such as the brain and lungs following acute ischemic or thrombotic events.
Contact: ImaRx Therapeutics, Inc. Greg Cobb, Chief Financial Officer, 520-770-1259 gcobb@imarx.com or Lippert/Heilshorn & Associates Bruce Voss or Don Markley, 310-691-7100 dmarkley@lhai.com
Source: ImaRx Therapeutics, Inc.
